Conditioned market authorization in China on February 5, 2021
üThe results of pre-clinical and clinical research trials were published in Science and Lancet Infect Diseases.
üThe result of Phase Ⅰ/Ⅱ/Ⅲ Clinical Trial showed that CoronaVac® has good safety and immunogenicity for all ages.
üThe Phase Ⅲ Clinical Trial and real-world studies showed that vaccination with CoronaVac has a significant impact on reducing the incidence, hospitalization and death rate caused by COVID-19 infection.
üThe inactivated COVID-19 Vaccine, CoronaVac®, was approved for WHO Emergency Use Listing (EUL).
üThe annual production capacity is over 2 billion doses, and CoronaVac® has been approved for emergency use in over 50 countries/regions/organizations around the world.
üAs of November 2021, the cumulative global supply of CoronaVac more than 2.3 billion doses, and the cumulative vaccinated doses reached 1.9 billion. It is currently the largest supplied and vaccinated COVID-19 vaccine in China and worldwide, and the China’s COVID-19 vaccine with the largest export amount globally.